Arcadia Biosciences' Q4 revenue falls 26%, net loss narrows
Overview
U.S. wellness products maker's Q4 revenue fell 26% yr/yr due partly to lower Zola and absence GLA oil sales
Net loss attributable to common stockholders narrowed, helped by lower SG&A expenses
Roosevelt Resources ended proposed merger with Arcadia; co raised $2.1 mln via preferred options
Outlook
Company intends to use recent proceeds to grow Zola coconut water brand and evaluate strategic alternatives
Arcadia says it will require additional funding in the near future to continue operations
Result Drivers
LOWER ZOLA AND GLA OIL SALES - Q4 revenue decline was in part due to lower Zola sales and absence of GLA oil sales compared to prior year
SG&A EXPENSE REDUCTION - Lower selling, general, and administrative expenses contributed to improved net loss
ZOLA SALES GROWTH (FULL YEAR) - Zola revenues rose 17% yr/yr for 2025, driven by increased distribution and higher sales volume
Company press release: ID:nGNX3sSrfp
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $901,000 |
|
Q4 Net Income |
| -$1.34 mln |
|
Q4 Operating Expenses |
| $2.28 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
